Sessions

Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion
Workforce of the Future: Talent, Change Management and Enabling Future Development
Delivering Projects and Managing Timelines in the Variable, Continuously Changing Environment Of Cell and Gene Therapy
How to Market my Biotech to Investors: Lessons Learned from Successful Investment and Funding Rounds
Moving the Industry Towards Automated Systems for Scale-up Success
Tech Review: New Platforms and Closed-Systems to Enable Commercial Success
Working With a CDMO is not Just an Outsourcing Contract but a Partnership: Learnings from Successful Biotech/CDMO Partnerships
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation
Overcoming Challenges and Setting Up for Success on the Path to Commercialisation

Patient and Payer Challenges: Enabling Access to Patients through Market Access, Pricing and Patient-Led Discussion

28 Jan 2022
11:00

11:00 Chairperson’s Opening
Lucas De Breed, Managing Director, August Care

11:05 Paying for Value in the Context of Advanced Therapies

  • Review of value-based models
  • Need for financial efficiency in managing effectiveness uncertainty
  • Five year outlook

Lucas De Breed, Managing Director, August Care

11:20 Appropriate and Timely Access to Patients:  Lessons Learned with CAR-T Therapies

  • Few slides on Instil Bio and our cell therapy (ITIL-168) – how we are similar yet different from the CAR-Ts
  • Topline discussion on how Instil is preparing the market for appropriate and timely patient access to our therapy (payer engagement, hospital reimbursement processes planning, patient support, etc.)
  • Lessons learned on how patient access rolled out for the first CAR-Ts

John Schick, Vice President, Global Market Access, InstilBio

11:35 Value Demonstration Challenges for Gene Therapy for Blood Disorders: Lessons Learned and New Approaches

  • Bringing a one-time potentially curative therapy to a chronic disease with history of limited treatment options has inherent value demonstration challenges
  • Learnings to date from various geographies indicate remaining high hurdles to convince payers of paying appropriately for gene therapies
  • Proper investment in real-world evidence, and related communications of that evidence, to best characterize disease unmet needs is critical to ensure patient access and commercial success

Clark Paramore, Head of Value Determination, Vice President of HEOR, bluebird bio

11:50 Emily’s Path To Car-T and Now Paying It Forward

  • Emily’s journey and our insurance cost
  • Emily Whitehead Foundation-Educating other families on how to find a trial and helping them get to treatment
  • Spreading awareness to help get global accessibility
  • Update on Emily today

Tom Whitehead, Founder, Emily Whitehead Foundation

12:05  Speaker Q&A and Panel Discussion

 

Speakers

Lucas De Breed
Founder and Managing Director
August Care
John Schick
Vice President, Global Market Access and Policy
Instil Bio
Clark Paramore
Head of Value Demonstration, Vice President of HEOR
bluebird bio